An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Tipifarnib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Kura Oncology
- 10 Jun 2017 Biomarkers information updated
- 14 Mar 2017 According to a Kura Oncology media release, data expected during the first half of 2018.
- 14 Mar 2017 According to a Kura Oncology media release, based on anecdotal evidence of hematological improvement observed in several patients,company has amended the study to evaluate further dose regimens to optimize those initial findings.